[ORGANIZATION]

The Lancet Diabetes & Endocrinology

Featured in 2 tracked stories · first seen 6 days ago

Situations

[ACTIVE] [HEALTH] [BUSINESS] [CRIME] [US] [BR] [GB]

GLP‑1 market, usage, safety & new guidance

182 clusters · 649 sources · last updated about 7 hours ago

Latest: Brazil's SUS delays rollout of GLP‑1 weight‑loss drugs

GLP‑1 receptor agonists dominate modern obesity and diabetes therapy, now reaching primary‑care, tele‑health and Medicare, with the market projected near $105 bn by 2030. Safety monitoring confirms a modest alopecia sign

[ACTIVE] [HEALTH] [BR] [MX] [US]

Obesity drug advances and health assessment

2 clusters · 11 sources · last updated 7 days ago

Latest: Obesity Treatment Advances Redefine Health Metrics

A July 22 review of 262 randomized trials involving nearly 100,000 adults found that the newest anti‑obesity medicines—particularly tirzepatide and semaglutide—produce the greatest weight loss but also raise rates of gas